Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.580 GeneticVariation disease BEFREE For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype. 30878754 2019
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.580 GeneticVariation disease BEFREE In the 2016 WHO classification of diffuse glioma, the diagnosis of an (anaplastic) oligodendroglioma requires the presence of both an IDH mutation (mt) and 1p/19q codeletion, whereas (anaplastic) astrocytoma are divided in IDH wild-type and IDHmt tumors. 30072066 2018
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.580 Biomarker disease BEFREE Today, the diagnosis of anaplastic oligodendroglioma requires the presence of both IDH-mt and 1p/19q co-deletion, whereas anaplastic astrocytoma is divided into IDH wild-type ( IDH-wt) and IDH-mt tumors. 28640702 2017
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.580 GeneticVariation disease BEFREE Our study indicates that the combination of sequential treatment with radiation and temozolomide might provide a favorable outcome in the case of 1p/19q-codeleted spinal anaplastic oligodendrogliomas and that molecular analysis can be beneficial in guiding treatment strategies, although the impact of IDH mutations on these tumors is still unclear. 26352098 2016
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.580 GeneticVariation disease BEFREE The R132H IDH1 mutation was identified in 43/117 tumor samples and R172K IDH2 mutation was detected in only one anaplastic oligodendroglioma. 27268645 2016
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.580 GeneticVariation disease BEFREE Anaplastic oligoastrocytoma and anaplastic astrocytoma patients with IDH gene mutation showed similar prognosis with anaplastic oligodendroglioma patients with wild-type IDH gene. 24149775 2014
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.580 GeneticVariation disease BEFREE However, no specific imaging pattern could be identified for the 1p/19q-codeleted AO or the IDH-mutated AO. 24353325 2014
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.580 Biomarker disease ORPHANET Anaplastic oligoastrocytoma and anaplastic astrocytoma patients with IDH gene mutation showed similar prognosis with anaplastic oligodendroglioma patients with wild-type IDH gene. 24149775 2014
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.580 Biomarker disease ORPHANET Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. 23681562 2013
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.580 GeneticVariation disease BEFREE Studies have identified several molecular abnormalities with clinical or biological relevance to AOD (e.g. t(1;19)(q10;p10), IDH1, IDH2, CIC and FUBP1 mutations).To better characterize the clinical and biological behavior of this tumor type, the creation of a national multicentric network, named "Prise en charge des OLigodendrogliomes Anaplasiques (POLA)," has been supported by the Institut National du Cancer (InCA). 23071531 2012
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.580 Biomarker disease ORPHANET Moving toward molecular classification of diffuse gliomas in adults. 23109653 2012
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.580 Biomarker disease ORPHANET Molecular diagnostics of gliomas: state of the art. 20714900 2010
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.580 Biomarker disease CTD_human IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. 20160062 2010
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.580 Biomarker disease ORPHANET Molecular classification of low-grade diffuse gliomas. 21075857 2010
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.580 Biomarker disease ORPHANET We found 165 IDH1 (72.7%) and 2 IDH2 mutations (0.9%) in 227 diffuse astrocytomas WHO grade II, 146 IDH1 (64.0%) and 2 IDH2 mutations (0.9%) in 228 anaplastic astrocytomas WHO grade III, 105 IDH1 (82.0%) and 6 IDH2 mutations (4.7%) in 128 oligodendrogliomas WHO grade II, 121 IDH1 (69.5%) and 9 IDH2 mutations (5.2%) in 174 anaplastic oligodendrogliomas WHO grade III, 62 IDH1 (81.6%) and 1 IDH2 mutations (1.3%) in 76 oligoastrocytomas WHO grade II and 117 IDH1 (66.1%) and 11 IDH2 mutations (6.2%) in 177 anaplastic oligoastrocytomas WHO grade III. 19554337 2009
Entrez Id: 3418
Gene Symbol: IDH2
IDH2
0.580 Biomarker disease ORPHANET IDH1 and IDH2 mutations in gliomas. 19228619 2009
Entrez Id: 3417
Gene Symbol: IDH1
IDH1
0.400 GeneticVariation disease BEFREE For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype. 30878754 2019
Entrez Id: 3417
Gene Symbol: IDH1
IDH1
0.400 GeneticVariation disease BEFREE In the 2016 WHO classification of diffuse glioma, the diagnosis of an (anaplastic) oligodendroglioma requires the presence of both an IDH mutation (mt) and 1p/19q codeletion, whereas (anaplastic) astrocytoma are divided in IDH wild-type and IDHmt tumors. 30072066 2018
Entrez Id: 3417
Gene Symbol: IDH1
IDH1
0.400 Biomarker disease BEFREE Today, the diagnosis of anaplastic oligodendroglioma requires the presence of both IDH-mt and 1p/19q co-deletion, whereas anaplastic astrocytoma is divided into IDH wild-type ( IDH-wt) and IDH-mt tumors. 28640702 2017
Entrez Id: 3417
Gene Symbol: IDH1
IDH1
0.400 GeneticVariation disease BEFREE Our study indicates that the combination of sequential treatment with radiation and temozolomide might provide a favorable outcome in the case of 1p/19q-codeleted spinal anaplastic oligodendrogliomas and that molecular analysis can be beneficial in guiding treatment strategies, although the impact of IDH mutations on these tumors is still unclear. 26352098 2016
Entrez Id: 3417
Gene Symbol: IDH1
IDH1
0.400 GeneticVariation disease BEFREE The R132H IDH1 mutation was identified in 43/117 tumor samples and R172K IDH2 mutation was detected in only one anaplastic oligodendroglioma. 27268645 2016
Entrez Id: 3417
Gene Symbol: IDH1
IDH1
0.400 GeneticVariation disease BEFREE Not only morphological and immunohistochemical examinations, but also cytogenetical investigations for IDH1/2 mutation, 1p/19q loss, and PTEN alteration, are strongly supportive methods for the differential diagnosis of small cell glioblastoma and anaplastic oligodendroglioma. 23979650 2014
Entrez Id: 3417
Gene Symbol: IDH1
IDH1
0.400 GeneticVariation disease BEFREE However, no specific imaging pattern could be identified for the 1p/19q-codeleted AO or the IDH-mutated AO. 24353325 2014
Entrez Id: 3417
Gene Symbol: IDH1
IDH1
0.400 GeneticVariation disease BEFREE Anaplastic oligoastrocytoma and anaplastic astrocytoma patients with IDH gene mutation showed similar prognosis with anaplastic oligodendroglioma patients with wild-type IDH gene. 24149775 2014
Entrez Id: 3417
Gene Symbol: IDH1
IDH1
0.400 Biomarker disease BEFREE Combining two biomarkers, IDH1/2 and 1p/19q codeletion, makes it possible to stratify AO in three groups with very distinct prognostic features. 23681562 2013